New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 10, 2014
08:37 EDTADMSAdamas Pharmaceuticals presents positive results from ADS-5102 study
Adamas Pharmaceuticals presented data on the rater and subject training process utilized in the Phase 2/3 EASED safety and efficacy study of ADS-5102 for the treatment of levodopa-induced dyskinesia, a condition characterized by involuntary movements without purpose that can become severely disabling, rendering individuals with Parkinson's disease unable to perform routine daily tasks. The Phase 2/3 EASED study met its primary endpoint and the efficacy results of ADS-5102 were aligned across all outcome measures. In addition, ADS-5102 was generally well tolerated with reported adverse events consistent with Parkinson's disease and the known amantadine safety profile.
News For ADMS From The Last 14 Days
Check below for free stories on ADMS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 13, 2014
16:21 EDTADMSAdamas Pharmaceuticals names Jeffrey Knapp as COO, William Dawson as CFO
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use